You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations.
Click “OK” to confirm you are a Healthcare Professional.
The IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter provides unparalleled effectiveness and safety, with 75% of patients re-intervention free at five years.1
IN.PACT global full cohort five-year freedom from CD-TLR rate: 69.4%2
Note: Provisional stent rate for IN.PACT Admiral is 42.5% and is for Lutonix 65.2%.9,13
™Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. The approved product name for the drug-coated balloon is IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter.
Patency rates from clinical trials may be calculated differently. Chart is for illustrative purposes only and results may differ in head-to-head comparison, and therefore may not be predictive of clinical results.
Primary patency is defined as freedom from CEC-adjudicated clinically driven TLR and from core lab-adjudicated binary restenosis. Patency per Kaplan-Meier estimates at 12 months (day 365).
Primary patency based on intent-to-treat (ITT) analysis. Primary patency is defined as freedom from clinically driven target lesion revascularization and freedom from restenosis as determined by duplex ultrasound-derived PSVR ≤ 2.4. Indication statement for IN.PACT Admiral (Japan): This device, IN.PACT Admiral Drug Coated Balloon Catheter, is indicated for percutaneous transluminal angioplasty of de novo and non-stented restenotic lesions with length ≤ 200 mm in superficial femoral and popliteal arteries with reference vessel diameters of ≥ 4 mm and ≤ 7 mm.
Primary patency based on intent-to-treat (ITT) analysis. Primary patency per Kaplan-Meier estimate is not available. Primary patency is defined as the absence of binary restenosis (as adjudicated by a blinded core lab) and freedom from target lesion revascularization. Indication statement for Lutonix (Japan): This device, Lutonix Drug-Coated Balloon Catheter, is indicated for treatment of de novo or restenotic lesion with a reference vessel diameter ≥ 4 mm and ≤ 6 mm and a length ≤ 15 cm in the native femoropopliteal artery (excluding in-stent lesion) to improve luminal diameter and to reduce restenosis.
1 Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. 5-year results from the IN.PACT SFA Trial. Circ Cardiovasc Interv. June 2019;12(6):e007702.
2 Tepe G. 5-year results from the IN.PACT Global Study Prespecified Cohorts: ISR, CTO and Long Lesions. Presented at VIVA, 2021.
3 Schneider PA, Laird J, Tepe G, et al. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial. Circ Cardiovasc Interv. January 2018;11(1):e005891.
4 Mathews SJ. 1- and 2-Year Outcomes. Presented at NCVH 2018. New Orleans, LA.
5 Mathews SJ. 3-Year Outcomes. Presented at NCVH 2019. New Orleans, LA.
6 Primary Patency is listed as reported in the IFU. Lutonix BAW1387400r9 Section 10.3.5 Table 7.
7 Brodmann M. 1 Year Outcomes. Presented at LINC 2020; Leipzig, Germany.
8 Sachar R. 2 Year Outcomes. Presented at VIVA 2020; Las Vegas, NV.
9 IN.PACT Admiral IFU M052624T001. Rev. 1G.
10 Lutonix IFU:BAW1387400r3, Primary patency per KM analysis at day 365.
11 Brodmann M, Keirse K, Scheinert D, et al. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort. JACC Cardiovasc Interv. October 23, 2017;10(20):2113-2123.
12 Lutonix IFU: BAW1387400r9.
13 Lutonix IFU BAW1387400r9 - Table 33: Procedural Data (Bailout Spot Stent used Post-DCB Dilatation, 65.2% (45/69).
14 Iida O, Soga Y, Urasawa K, et al. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial. J Endovasc Ther. February 2018;25(1):109-117.
15 Bard Data: 1-year outcomes from the LEVANT Japan Trial. Pharmaceuticals and Medical Devices Agency. Available at: http://www.pmda.go.jp/medical_devices/2017/M20170830001/780045000_22900BZX00252000_A100_1.pdf. (in Japanese). Accessed March 23, 2022.
16 Lutonix IFU: BAW1387400r5.
17 Stellarex IFU No. P011966.
DCB publication landscape
Medtronic IN.PACT Admiral DCB
18 Tepe G, et al. Circulation. 2015;131:495-502.
19 Iida O, et al. J Endovasc Ther. 2018;25:109-117.
20 Chen Z, et al. J Endovasc Ther. 2019;26:471-478.
21 Zeller T, et al. Circ Cardiovasc Interv. 2019;12:e007730.
22 Shishehbor MH, et al. J Vasc Surg. 2019;70:1177-1191.e9.
23 Kobe DS, et al. J Invasive Card. 2020;32:243-248.
24 Laird JR, et al. J Am Coll Cardiol. 2015;66:2329-2338.
25 Iida O, et al. Catheter Cardiovasc Interv. 2019;93:664-672.
26 Schneider PA, et al. Circ Cardiovasc Interv. 2018;11:e005891.
27 Soga Y, et al. J Endovasc Ther. 2020;27:946-955.
28 Laird JA, et al. Circ Cardiovasc Interv. 2019;12:e007702.
29 Schneider PA, et al. J Am Coll Cardiol. 2019;73:2550-2563.
30 Brodmann M, et al. JACC Cardiovasc Interv. 2017;10:2113-2123.
31 Scheinert D, et al. Circ Cardiovasc Interv. 2018;11:e005654.
32 Tepe G, et al. JACC Cardiovasc Interv. 2019;12:484-493.
33 Ansel GM, et al. J Endovasc Ther. 2018;25:673-682.
34 Reijnen MMPJ, et al. J Endovasc Ther. 2019;26:305-315.
35 Micari A, et al. JACC Cardiovasc Interv. 2018;11:945-953.
36 Salisbury AC, et al. JACC Cardiovasc Interv. 2016;9:2343-2352.
37 Pietzsch JB, et al. Cardiovasc Intervent Radiol. 2022;45:298-305.
38 Torsello G, et al. J Endovasc Ther. 2020;27:693-705.
39 Kohi M, et al. J Vasc Interv Radiol. 2020;31:1410-1418.e10.
40 Schneider PA, et al. Catheter Cardiovasc Interv. 2020;96:1087-1099.
BD Lutonix DCB
41 Rosenfield K, et al. N Engl J Med. 2015;373:145-153.
42 Scheinert D, et al. J Endovasc Ther. 2016;23:409-416.
43 Scheinert D, et al. JACC Cardiovasc Interv. 2014;7:10-19.
44 Thieme M, et al. JACC Cardiovasc Interv. 2017;10:1682-1690.
45 Ouriel K, et al. JACC Cardiovasc Interv. 2019;12:2515-2524.
Philips Stellarex DCB
46 Krishnan P, et al. Circulation. 2017;136:1102-1113.
47 Schroeder H, et al. Circulation. 2017;135:2227-2236.
48 Schroë H, et al. Catheter Cardiovasc Interv. 2018;91:497-504.
49 Brodmann M, et al. JACC Cardiovasc Interv. 2018;11:2357-2364.
50 Schroeder H, et al. Catheter Cardiovasc Interv. 2015;86:278-286.
51 Grey WA, et al. Circulation. 2019;140:1145-1155.
52 Lyden SP, et al. J Endovasc Ther. Published online January 8, 2022.
53 Lyden SP, et al. J Vasc Surg. 2022;75:600-607.
Boston Scientific Ranger DCB
54 Sachar R, et al. JACC Cardiovasc Interv. 2021;14:1123-1133.
55 Steiner S, et al. JACC Cardiovasc Interv. 2018;11:934-941.
56 Lichtenberg M, et al. J Cardiovasc Surg (Torino). 2018;59:45-50.
57 Steiner S, et al. Eur Heart J. 2020;41:2541-2552.